Ontology highlight
ABSTRACT: Objective
Persons with schizophrenia exhibit greater neurocognitive test score dispersion. Here, we seek to characterize dispersion on the Neurocognitive Composite subtests of the Measurement of Treatment Research to Improve Cognition in Schizophrena Consensus Cognitive Battery (MCCB) and determine the relative effects of different antipsychotic formulations on dispersion and mean performance.Method
In this post hoc analysis of the DREaM study (NCT02431702), which compared treatment with paliperidone palmitate (PP) long-acting injectable with oral antipsychotic (OAP) treatment over 18 months, dispersion in MCCB neurocognitive subtest performance was calculated for each participant by visit (test occasion).Results
Over 18 months, mean neurocognitive performance impro
SUBMITTER: Williamson DJ
PROVIDER: S-EPMC9468588 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature